BMY - Bristol-Myers Squibb Company

NYSE · Healthcare · Drug Manufacturers—General

$57.13

Market Closed

End of day · Jun 12, 2026, 12:00 AM

Active

Resolved

Bull

Bear

About

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; Orencia for adult patients with active RA and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Onureg for the treatment of adult patients with AML; Inrebic, an oral kinase inhibitor indicated for the treatment of myelofibrosis; Camzyos for the treatment of adults with symptomatic obstructive HCM to enhance functional capacity and symptoms; Sotyktu for the treatment of adults with moderate-to-severe plaque psoriasis; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane, a protein-bound chemotherapy product. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

https://www.bms.com

BMY - Bristol-Myers Squibb Company

Healthcare

Bristol Myers (BMY) has been making a bit of a comeback since that big dip last summer. If you look at the last year, shares dropped hard into the low 40s by late July and then spent months fighting back. That rebound wasn't exactly smooth sailing but now the stock's back near 57, and people seem to notice BMY means business again. I’m bullish here into the next couple months and targeting 67.00. The main reason: the pipeline is starting to actually deliver, with new approvals and some late stage drugs that should move the revenue needle. Even with patent cliffs looming (they always loom with big pharma), BMY has kept earnings quite steady, plus the dividend is no joke. On top of that, a lot of negativity seems priced in after that drawdown. It's still trading under historic multiples for a name like this. What could mess this up? Pipeline risk is real, and if one of their big studies flops or the FDA has issues, that’ll sting. Also, buyout rumors can get weird with these valuations, but I wouldn't count on them as a positive. Near term catalyst is the next earnings print in about 6 weeks. Management will address both the pipeline and cost control, and if they beat and give any sort of upside, I think funds pile back in. Feels like the market is ready to believe in large cap pharma again, and BMY is a cheap way to play that reversal just don’t expect fireworks overnight.

Entry

$56.91

Above

$67.00

Aug 8, 2026

Karma

122 to 17261

Bullish

Open

Vote